| 引用本文: | 杨清默,黄于凡,陈双龙,陈文霖,欧阳忠.聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的应用比较[J].中国现代应用药学,2018,35(8):1221-1224. |
| YANG Qingmo,HUANG Yufan,CHEN Shuanglong,CHEN Wenlin,OUYANG Zhong.Pegylated Liposomal Doxorubicin and Epirubicin Used in Neoadjuvant Chemotherapy of Breast Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(8):1221-1224. |
|
| 本文已被：浏览 3109次 下载 2161次 |
码上扫一扫！ |
|
|
| 聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的应用比较 |
|
杨清默,黄于凡,陈双龙,陈文霖,欧阳忠
|
|
厦门大学附属第一医院乳腺外科,厦门大学附属第一医院乳腺外科,厦门大学附属第一医院乳腺外科,厦门大学附属第一医院乳腺外科,厦门大学附属第一医院乳腺外科
|
|
| 摘要: |
| 目的 比较聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的疗效及不良反应。方法 回顾性分析2015年1月-12月行乳腺癌AC-T或EC-T新辅助化疗的146例患者，其中应用聚乙二醇多柔比星脂质体86例，应用表柔比星60例，分析其临床病理特征、化疗效果及不良反应，并应用Logistic回归分析影响新辅助化疗疗效的因素。结果 聚乙二醇多柔比星脂质体组与表柔比星组临床病理特征一致，无统计学差异。2组新辅助化疗的疗效无统计学差异。HER-2状态是影响新辅助化疗疗效的主要因素。聚乙二醇多柔比星脂质体组的白细胞降低、消化道反应、脱发及心电图异常等不良反应较表柔比星组明显减少，而手足综合征则明显增多，具有统计学差异。结论 聚乙二醇多柔比星脂质体与传统的表柔比星在乳腺癌新辅助化疗中疗效一致。 |
| 关键词: 聚乙二醇多柔比星脂质体 表柔比星 乳腺癌 新辅助化疗 |
| DOI：10.13748/j.cnki.issn1007-7693.2018.08.023 |
| 分类号:R965 |
| 基金项目:国家自然科学基金项目（81672595） |
|
| Pegylated Liposomal Doxorubicin and Epirubicin Used in Neoadjuvant Chemotherapy of Breast Cancer |
|
Qing-Mo Yang,Yu-Fan Huang,Shuang-Long Chen,Wen-Lin Chen and Zhong Ou-Yang
|
|
Department of Breast Surgery,The First Affiliated Hospital of Xiamen University,Department of Breast Surgery,The First Affiliated Hospital of Xiamen University,Department of Breast Surgery,The First Affiliated Hospital of Xiamen University,Department of Breast Surgery,The First Affiliated Hospital of Xiamen University,Department of Breast Surgery,The First Affiliated Hospital of Xiamen University
|
| Abstract: |
| OBJECTIVE To investigate the effect of pegylated liposomal doxorubicin and epirubicin used in neoadjuvant chemotherapy of breast cancer. METHODS The 146 patients who accepted neoadjuvant chemotherapy of breast cancer from 2015 January to 2015 december were analyzed, 86 of them received pegylated liposomal doxorubicin, and 60 of them received epirubicin. Compared the clinicopathologic feature, curative effect and untoward effect of drugs between two groups. Logistic regression analysis was used to analyze the factors influencing neoadjuvant chemotherapy. RESULTS Clinicopathologic feature of two groups had no difference. Pegylated liposomal doxorubicin's curative effect was in accordance with epirubicin's. The HER-2 state was the main factors affecting curative effect. Pegylated liposomal doxorubicin's untoward effect such as leukopenia, vomiting, alopecia and electrocardiographic abnormality was less than epirubicin's. But pegylated liposomal doxorubicin's hand-foot skin reaction was much more than epirubicin's. CONCLUSION The efficacy of pegylated liposomal doxorubicin is comparable to conventional anthracycline in neoadjuvant chemotherapy of breast cancer. |
| Key words: pegylated liposomal doxorubicin epirubicin breast cancer neoadjuvant chemotherapy |
